FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Reiterates Buy Opinion On Shares Of News Corp

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price by $2 to $31, 26x our FY 27 (Jun.) EPS estimate (unchanged multiple). We raise our FY 26 EPS estimate to $1.03 from $0.99 and FY 27's to $1.19 from $1.13. Following FQ3 (Mar-Q) results, we are reiterating our Buy opinion. We are encouraged by results at Dow Jones, where revenue growth is accelerating in its Risk & Compliance (+19% Y/Y) and Energy (+12% Y/Y) products. The Dow Jones segment also saw Wall Street Journal subscriptions reach 4.7M (+8% Y/Y) despite higher subscription prices, demonstrating pricing power. The company's Digital Real Estate Services grew revenue (+8% Y/Y ex-FX) despite new and existing home sales remaining in a slump. Adjusted EBITDA margins have expanded for eight consecutive quarters post-Foxtel spin-off, fueling improved free cash flow and accelerated buybacks. At 26x our FY 27 estimate vs. a 29x five-year average, shares trade at a discount with potential for re-rating as operational momentum continues.

Related Articles

Research

Research Alert: CFRA Keeps Hold View On Shares Of Moderna; Shares +16% Amid Andes Outbreak

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:MRNA shares rose over 16% in five days following an Andes virus (rare hantavirus strain) outbreak on cruise ship MV Hondius. The vessel, carrying ~150 passengers from 23 countries, departed Argentina on April 1 and docked in the Canary Islands on May 10 with six confirmed cases, two probable cases, and three deaths. While no hantavirus vaccine currently exists, mRNA technology offers advantages including rapid development, strain adaptability, and stronger immune response versus traditional vaccines. Moderna is developing an mRNA hantavirus vaccine with Korea University, though the program remains in early preclinical stages (animal studies only), suggesting substantial time is needed despite current market enthusiasm. Health officials assess the pandemic risk as low given the virus requires close, prolonged contact for transmission. The Andes virus is the only known hantavirus strain to spread person-to-person. We raise our target to $58 from $48 based on NPV analysis, maintain our 2026 LPS at -$7.95, and keep 2027 LPS at -$4.82.

$MRNA
Research

Research Alert: CFRA Cuts Opinion On Shares Of Ingredion Incorporated To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our 12-month target to $119 from $137, ~11x our 2026 EPS of $10.83 (cut from $11.43; 2027 EPS cut to $11.84 from $12.37) vs. the 13x long-term mean. Our revised outlook reflects ongoing challenges at the Argo facility, one of the company's largest manufacturing sites. In April 2026, this facility experienced its third major disruption in 18 months. While management has characterized these as separate incidents, the pattern suggests underlying operational issues. This latest disruption and associated costs prompted the company to lower its full-year EPS guidance. Additional headwinds include Mexican peso strength (costs are peso-denominated), rising energy prices, packaging inflation, tariffs, and concerns about indirect impacts on consumer demand in 2H 2026. Given the prolonged margin recovery in the F&II-U.S./Canada segment, we believe it is prudent to move to a Hold rating.

$INGR
Research

Research Alert: CFRA Keeps Hold Rating On Shares Of Genpact Limited

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price by $9 to $36, 8.3x our 2027 EPS estimate vs. G's three-year historical forward P/E average of 12.1x and the peer average of 11.6x. We raise our 2026 EPS view to $4.04 from $3.99 and keep 2027's unchanged at $4.34. We think G faces operational risks, including execution hurdles in scaling its new AI-driven offerings against intense competition. However, these concerns are partly overshadowed by the exceptional momentum in its strategic pivot, highlighted by a 24% surge in ATS revenue. In a major proof point of this shift, the company secured nearly double the contract value for its new Agentic solutions in Q1 alone compared to all of 2025, demonstrating rapid market adoption. This successful transition towards higher-margin, IP-based recurring revenue is structurally improving profitability, evidenced by 12 consecutive quarters of gross margin expansion. Sustaining this high-stakes execution and improving cash conversion remain critical to fully de-risking the company's transformation.

$G